FDA should reassess postmarket trials for cancer drugs approved via accelerated pathway, researchers say
The FDA may need to reassess how confirmatory trials are conducted after just one-fifth of such trials for cancer drug indications approved via the FDA …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
